Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan

[1]  John P Klein,et al.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.

[2]  H. Inoko,et al.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. , 2002, Blood.

[3]  H. Dohy,et al.  Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation , 2001, Bone Marrow Transplantation.

[4]  J. Fay,et al.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.

[5]  M. Horowitz,et al.  Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  K. Kawa,et al.  Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia , 1999, Bone Marrow Transplantation.

[7]  R A Nash,et al.  Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[9]  M. Labopin,et al.  Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1997, Transplantation proceedings.

[10]  A. Deisseroth,et al.  Tacrolimus and Minidose Methotrexate for Prevention of Acute Graft- Versus-Host Disease After Matched Unrelated Donor Marrow Transplantation , 1996 .

[11]  M. Labopin,et al.  Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[12]  J. Fay,et al.  FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.

[13]  R. Collins,et al.  FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. , 1996, Blood.

[14]  R A Nash,et al.  Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. , 1995, Blood.

[15]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[16]  M. Tanimoto,et al.  Low incidence of acute GVHD in patients transplanted with marrow from HLA-A,B,DR-compatible unrelated donors among Japanese. , 1995, Bone marrow transplantation.

[17]  A. Nademanee,et al.  Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.

[18]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[19]  E. A. O'neill,et al.  FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin , 1992, Nature.

[20]  G. Crabtree,et al.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A , 1991, Nature.

[21]  M. Pepe,et al.  What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? , 1990 .

[22]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[23]  H. Deeg,et al.  Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial , 1989, British journal of haematology.

[24]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[25]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[26]  G. Gahrton,et al.  A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. , 1986, Bone marrow transplantation.

[27]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[28]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.